Free PDFs of my two text books, direct link for downloads, http://159.69.48.3/
Physiology book in hard copy
https://www.ebay.co.uk/itm/154770452796?mkevt=1&mkcid=16&mkrid=710-127635-2958-0
0:00 start
1:25 it is essential that health care practitioners review all data
1:45 to evaluate risk and benefits, unique to each patient
2:11 when determining what health care services to provide,
2:37 including the administration of covid-19 vaccines
2:53 these decisions should be made on an individual basis (Topic on providing unique care according to individual needs)
3:15 risk of administering a covid-19 vaccine to healthy children may outweigh the benefits
3:25 Healthy children aged 5 to 17 may not benefit from receiving the currently available COVID-19 vaccine
3:39 children with underlying conditions are the best candidates for the COVID-19 vaccine
Looking at the evidence
4:00 risk that may outweigh benefits among healthy children with no underlying conditions
4:12 limited risk of severe illness due to COVID-19
5:00 Keynotes: Paper was used in Delta times, you ideally want something more current. The following are points true according to delta times
5:34 Although Covid-19 is generally milder in children than adults
5:39 severe illness and long-term complications, including multisystem inflammatory syndrome in children (MIS-C), can occur after primary infection
6:11 Evaluation of the BNT162b2 Covid-19 Vaccine in children 5 to 11 years of AGE (NEJM)
8:42 argument: There is high prevalence of existing immunity among children
11:18 The absence of data informing benefit of COVID-19 vaccination among children with existing immunity (agrees with the Florida study)
12:19 in clinical trials, higher than anticipated serious adverse events occurred among those receiving the covid-19 vaccine. (reference unclear to this claim)
14:43 Reduced vaccine efficacy in with omicron, Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
16:27 the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11
16:48 However, vaccination of children 5-11 years was protective against severe disease and is recommended
17:53 Risk of myocarditis due to the COVID-19 vaccine, Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021 (JAMA, 2022)
20:19 Vaccine efficacy wanes rapidly (the percentage drop shown for children and adolescents)
21:40 Recommended for children with underlying health conditions or comorbidities
22:08 in general, healthy children with no significant underlying health conditions under 16 years old are at little to no risk of severe illness complications from covid-19, For adolescents, the risk of myocarditis du
Florida
https://floridahealthcovid19.gov/wp-content/uploads/2022/03/g2-jtr_QWBT4hJpqr.pdf?utm_source=floridahealth.gov&utm_medium=referral&utm_campaign=covid-19&utm_term=fdoh+issues+new+guidance+regarding+covid-19+vaccination+recommendations+for+children&utm_content=press_release&url_trace_7f2r5y6=hcgyu2mu94atfcyvdgsa
Children with underlying conditions are the best candidates for the COVID-19 vaccine.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)
(Delta time data)
https://www.nejm.org/doi/full/10.1056/nejmoa2116298
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (NEJM)
https://www.nejm.org/doi/full/10.1056/nejmoa2116298
N = 2,268, (phase 2 clinical trial)
https://covid19serohub.nih.gov
NIH covid SeroHub
https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
Reduced vaccine efficacy in with omicron
Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant
https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1
New York State Department of Health
December 13, 2021 to January 30, 2022
Aged 12 – 17, n = 852,384 fully-vaccinated
Aged, 5 – 11 years, n = 365,502 fully-vaccinated
Risk of myocarditis due to the COVID-19 vaccine
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021(JAMA, 2022)
https://jamanetwork.com/journals/jama/fullarticle/2788346
(70.7 per million doses of the BNT162b2 vaccine)
in adolescent males aged 16 to 17 years
(105.9 per million doses of the BNT162b2 vaccine)
in young men aged 18 to 24 years
(52.4 per million doses of BNT162b2)
(56.3 per million doses of
mRNA-1273 )
https://www.medrxiv.org/content/10.1101/2022.02.25.22271454v1
Source